Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.

BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.

HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.

Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.

Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.

Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.

Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.

Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.